70 related articles for article (PubMed ID: 476710)
21. Cisplatin, vinblastine, and bleomycin in the treatment of metastatic melanoma: a phase II study of the Southeastern Cancer Study Group.
Johnson DH; Presant C; Einhorn L; Bartolucci AA; Greco FA
Cancer Treat Rep; 1985; 69(7-8):821-4. PubMed ID: 2410120
[TBL] [Abstract][Full Text] [Related]
22. Phase I evaluation of piperazinedione in patients with advanced cancer.
Currie V; Woodcock T; Tan C; Krakoff I; Young C
Cancer Treat Rep; 1979 Jan; 63(1):73-6. PubMed ID: 369694
[TBL] [Abstract][Full Text] [Related]
23. Dose-escalation study of weekly 1-hour paclitaxel administration in patients with refractory cancer.
Chang AY; Boros L; Asbury R; Hui L; Rubins J
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-69-S17-71. PubMed ID: 9374098
[TBL] [Abstract][Full Text] [Related]
24. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
Ott PA; Chang JL; Oratz R; Jones A; Farrell K; Muggia F; Pavlick AC
Chemotherapy; 2009; 55(4):221-7. PubMed ID: 19451711
[TBL] [Abstract][Full Text] [Related]
25. Phase II evaluation of piperazinedione in metastatic breast carcinoma.
Palmer RL; Samal BA; Vaughn CB; Tranum BL
Cancer Treat Rep; 1977 Dec; 61(9):1711-2. PubMed ID: 340035
[No Abstract] [Full Text] [Related]
26. Evaluation of merbarone (NSC 336628) in disseminated malignant melanoma. A Southwest Oncology Group study.
Slavik M; Liu PY; Kraut EH; Natale RB; Flaherty LE; Sondak VK
Invest New Drugs; 1995; 13(2):143-7. PubMed ID: 8617577
[TBL] [Abstract][Full Text] [Related]
27. A randomized comparison of cyclophosphamide, DTIC with or without piperazinedione in metastatic malignant melanoma.
Presant CA; Bartolucci AA; Balch C; Troner M
Cancer; 1982 Apr; 49(7):1355-7. PubMed ID: 7037162
[TBL] [Abstract][Full Text] [Related]
28. Results of a phase II study of maytansine in patients with breast carcinoma and melanoma.
Cabanillas F; Bodey GP; Burgess MA; Freireich EJ
Cancer Treat Rep; 1979 Mar; 63(3):507-9. PubMed ID: 371803
[TBL] [Abstract][Full Text] [Related]
29. Phase II trial of piperazinedione (NSC 135758) in the treatment of advanced or recurrent carcinoma of the ovary. A Gynecologic Oncology Group study.
Thigpen JT; Blessing JA; Arseneau JC; Homesley HD
Am J Clin Oncol; 1984 Jun; 7(3):261-3. PubMed ID: 6547268
[TBL] [Abstract][Full Text] [Related]
30. Piperazinedione in metastatic renal carcinoma.
Pasmantier MW; Coleman M; Kennedy BJ; Eagan R; Carolla R; Weiss R; Leone L; Silver RT
Cancer Treat Rep; 1977 Dec; 61(9):1731-2. PubMed ID: 340039
[No Abstract] [Full Text] [Related]
31. A phase II trial of PCNU in patients with malignant melanoma and central nervous system metastases.
Feldman LD; Feun LG; Benjamin RS; Yap BS; Plager C; Papadopoulos N; Savaraj N; Burgess MA; Bodey GP
Am J Clin Oncol; 1985 Jun; 8(3):215-7. PubMed ID: 4050740
[TBL] [Abstract][Full Text] [Related]
32. Phase II trial of piperazinedione (NCS 135758) in the treatment of advanced or recurrent squamous cell carcinoma of the cervix. A Gynecologic Oncology Group study.
Thigpen JT; Blessing J; Homesley HD; Adcock LL
Am J Clin Oncol; 1983 Aug; 6(4):423-6. PubMed ID: 6688150
[TBL] [Abstract][Full Text] [Related]
33. Detorubicin--an active anthracycline in untreated metastatic melanoma.
Chawla SP; Legha SS; Benjamin RS
J Clin Oncol; 1985 Nov; 3(11):1529-34. PubMed ID: 4056844
[TBL] [Abstract][Full Text] [Related]
34. Mitozolomide (NSC 353451), a new active drug in the treatment of malignant melanoma. Phase II trial in patients with advanced disease.
Gundersen S; Aamdal S; Fodstad O
Br J Cancer; 1987 Apr; 55(4):433-5. PubMed ID: 3580266
[TBL] [Abstract][Full Text] [Related]
35. Phase-II study of recombinant alpha 2-interferon in advanced malignant melanoma.
Coates A; Rallings M; Hersey P; Swanson C
J Interferon Res; 1986 Feb; 6(1):1-4. PubMed ID: 2871116
[TBL] [Abstract][Full Text] [Related]
36. Phase II trial of piperazinedione in patients with advanced or recurrent uterine sarcoma. A Gynecologic Oncology Group study.
Thigpen JT; Blessing JA; Homesley HD; Hacker N; Curry SL
Am J Clin Oncol; 1985 Oct; 8(5):350-2. PubMed ID: 3840643
[TBL] [Abstract][Full Text] [Related]
37. Phase II trial of pyrazofurin in malignant melanoma.
Budman D; Currie V; Wittes R
Cancer Treat Rep; 1977 Dec; 61(9):1733-4. PubMed ID: 340040
[No Abstract] [Full Text] [Related]
38. Phase II trial of carboplatin in patients with metastatic malignant melanoma. A report from the Eastern Cooperative Oncology Group.
Chang A; Hunt M; Parkinson DR; Hochster H; Smith TJ
Am J Clin Oncol; 1993 Apr; 16(2):152-5. PubMed ID: 8452109
[TBL] [Abstract][Full Text] [Related]
39. Phase II evaluation of L-alanosine (NSC-153353) for patients with disseminated malignant melanoma.
Creagan ET; Long HJ; Ahmann DL; Green SJ
Am J Clin Oncol; 1984 Oct; 7(5):543-4. PubMed ID: 6507375
[TBL] [Abstract][Full Text] [Related]
40. Phase II study of tauromustine in disseminated malignant melanoma.
Nolte H; Gjedde SB; Lindegaard-Madsen E; Bergh J; Blomquist E; Mouridsen HT
Eur J Cancer Clin Oncol; 1989 Apr; 25(4):655-7. PubMed ID: 2714342
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
